Lipocine to present at A.G.P. virtual showcase

Lipocine Inc. filed a current report to note that its management will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. filed a current report to note that its management will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM.

The attached press release also highlights Lipocine’s oral drug-delivery focused pipeline, which includes candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth, as well as its FDA-approved oral testosterone product TLANDO for hypogonadism.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Fireside chat date: Wednesday, May 20, 2026 Fireside chat time: 3:00 PM Company phone: (801) 994-7383 +1 more

4 metrics

Fireside chat date Wednesday, May 20, 2026 A.G.P.’s Annual Healthcare Company Showcase

Fireside chat time 3:00 PM Scheduled presentation time at A.G.P. showcase

Company phone (801) 994-7383 Lipocine principal contact number

Investor contact phone (617) 430-7579 Investor relations contact listed in release

Key Terms

fireside chat, postpartum depression, major depressive disorder, essential tremor, +1 more

5 terms

fireside chat financial

"management will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase"

postpartum depression medical

"LPCN 1154 for the treatment of postpartum depression"

A mood disorder that can arise after childbirth, characterized by persistent sadness, anxiety, exhaustion and difficulty caring for oneself or a baby; it can range from moderate to severe and often requires medical or therapeutic treatment. Investors care because its prevalence affects demand for medical treatments, mental-health services and parental workplace policies, and can influence healthcare spending, drug development programs, and productivity in sectors that depend on caregiver labor — much like a widespread recurring expense that changes consumer and employer behavior.

major depressive disorder medical

"LPCN 2201 for treatment of major depressive disorder"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

essential tremor medical

"LPCN 2203 targeted for the management of essential tremor"

Essential tremor is a neurological condition that causes involuntary shaking, usually in the hands or arms, which can make everyday tasks difficult. While it is not life-threatening, it can impact a person's ability to perform precise movements. For investors, understanding such health conditions is important because they can influence a person's productivity, decision-making, and overall financial stability.

hypogonadism medical

"for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males"

Hypogonadism is a medical condition in which the body produces abnormally low levels of sex hormones because the glands that make them are underactive or not working properly. For investors, it matters because diagnosis and long-term treatment can drive demand for drugs, devices and tests, affect clinical trial activity and influence regulatory and reimbursement decisions—similar to how a faulty thermostat can create ongoing repair and replacement markets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine Inc. (LPCN) announce in this 8-K filing?

Lipocine announced that its management will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. The presentation highlights the company’s oral drug-delivery platform and development pipeline, and the related press release is furnished as Exhibit 99.1.

When will Lipocine (LPCN) present at A.G.P.’s Annual Healthcare Company Showcase?

Lipocine will participate in a fireside chat on Wednesday, May 20, 2026, at 3:00 PM. The event is part of A.G.P.’s Annual Healthcare Company Showcase, and investors can register for the conference and view the presentation through the link referenced in the announcement.

What is the focus of Lipocine Inc.’s business according to the filing?

Lipocine is a biopharmaceutical company using a proprietary technology platform to develop therapeutics with effective oral delivery. Its strategy centers on creating differentiated, patient-friendly oral options targeting large markets with significant unmet medical needs across several central nervous system and metabolic indications.

Which drug candidates are highlighted in Lipocine’s development pipeline in this document?

The pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 2401 for obesity management, LPCN 1148 for liver cirrhosis symptoms, and LPCN 1107 for prevention of preterm birth.

Which approved product from Lipocine is mentioned in the filing?

The filing notes TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, which is FDA-approved. TLANDO is indicated for adult males with conditions associated with deficiency of endogenous testosterone, commonly referred to as hypogonadism.

How can investors learn more or contact Lipocine according to this filing?

Investors are directed to visit www.lipocine.com for more information about the company. The press release also lists contacts including Krista Fogarty at (801) 994-7383 and an investor relations contact reachable at (617) 430-7579 and via email for additional inquiries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/18/2026 - 09:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 18, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On May 18, 2026, the Company issued a press release announcing Lipocine to present at A.G.P.’s Annual Virtual Healthcare Company Showcase on Wednesday, May 20, 2026. The press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description

99.1		Press Release announcing Lipocine to Present at A.G.P.’s Annual Virtual Healthcare Company Showcase

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIPOCINE INC.

Date:	May 18, 2026	By:	/s/ Mahesh V. Patel
			Mahesh V. Patel
			President and Chief Executive Officer

Exhibit 99.1

Lipocine to Present at A.G.P.’s Annual Virtual Healthcare Company Showcase

SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that management will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.

Fireside Chat Details:

Time: 3:00 PM ET

Date: Wednesday, May 20, 2026

Investors can register for the conference and view the fireside chat here.

About Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

SOURCE Lipocine Inc.

For further information:

Krista Fogarty

Phone: (801) 994-7383

kf@lipocine.com

Investors:

PJ Kelleher

Phone: (617) 430-7579

pkelleher@lifesciadvisors.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 EX-99.1 7.2 KB